2. Academic Validation
  3. NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages

NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages

  • Int Immunopharmacol. 2021 Mar;92:107358. doi: 10.1016/j.intimp.2020.107358.
Yuhua Shi 1,  Qian Lv 1,  Mengjie Zheng 1,  Hongxiang Sun 1,  Fushan Shi 2
Affiliations

Affiliations

  • 1 Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • 2 Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China; Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, Zhejiang University, Hangzhou 310058, Zhejiang, China. Electronic address: [email protected].
PMID: 33508701 DOI: 10.1016/j.intimp.2020.107358
Abstract

INF39 is a nontoxic, irreversible, acrylate-based NLRP3 Inhibitor and a further optimization of ethyl 2-((2-chlorophenyl) hydroxyl) methyl) acrylate (INF4E). However, the detail mechanism and the direct target of its anti-inflammatory activity is not clear. Here, we show that INF39 is a specific inhibitor for NLRP3 inflammasome activation. INF39 specifically suppresses NLRP3 activation but not the NLRC4 or AIM2 inflammasomes. INF39 has no effect on K+ efflux, ROS generation or mitochondrial membrane potential, which are the upstream events of NLRP3 inflammasome activation. In addition, INF39 has no direct inhibitory effect on GSDMD, which is the downstream event of inflammasomes. More importantly, INF39 inhibits the interaction of NEK7-NLRP3, and subsequently inhibits interaction of NLRP3-NLRP3, NLRP3-ASC, ASC oligomerization and speckle formation. Altogether, our study unveils a deeper anti-inflammatory mechanism for INF39 and suggests it could serve as a lead for developing novel therapeutics combating NLRP3-driven diseases.

Keywords

Anti-inflammation; INF39; Inflammasome; NLRP3 inflammasome.

Figures
Products